Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Fineline Cube Jul 17, 2026
Company Deals

Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline

Fineline Cube Jul 17, 2026
Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

Novartis’ Fabhalta Receives FDA Approval as First Oral Complement Factor B Inhibitor to Slow Renal Decline in Primary IgA Nephropathy

Fineline Cube Jul 17, 2026
Company Drug

Shionogi’s Fetroja Receives FDA Acceptance for Pediatric sNDA Expanding Use to Gram-Negative Infections in Hospital-Acquired Pneumonia and Complicated UTIs

Fineline Cube Jul 17, 2026
Company

Sanofi Reports 9.9% Sales Growth to EUR 43.6B, Driven by Dupixent and China

Fineline Cube Jan 30, 2026

Sanofi (NASDAQ: SNY) reported full‑year 2025 revenues of EUR 43.626 billion (USD 47.8 billion), representing 9.9% growth at constant exchange...

Company

Roche Reports 7% Sales Growth to CHF 61.5B, Driven by Pharma and China

Fineline Cube Jan 30, 2026

Roche (SWX: ROG, OTCMKTS: RHHBY) reported full‑year 2025 sales of CHF 61.5 billion : (USD 69.1 billion), representing 7% growth at...

Company Drug

United Labs TUL108 Gets FDA Nod for Antibiotic Resistance Trial

Fineline Cube Jan 29, 2026

United Laboratories International Holdings Ltd (HKG: 3933) announced that the U.S. Food and Drug Administration (FDA)...

Company Deals

Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China

Fineline Cube Jan 29, 2026

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced a licensing agreement with ApolloBio Corp.,...

Company Deals

Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform

Fineline Cube Jan 29, 2026

Chengdu Kanghua Biological Products Co., Ltd. (SHE: 300841) announced a plan to increase capital investment...

Company Deals

Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered

Fineline Cube Jan 29, 2026

Lisata Therapeutics announced the termination of its licensing agreement with Qilu Pharmaceutical Co., Ltd. for...

Company Deals

WuXi Biologics Partners with Sinorda on SND006 Bispecific Antibody for Autoimmune Diseases

Fineline Cube Jan 29, 2026

WuXi Biologics (HKG: 2269) announced a collaboration agreement with Guizhou Sinorda Biomedicineic Co., Ltd. to provide...

Company Deals

NeuShen Therapeutics Raises Series A+ for CNS Drug Development

Fineline Cube Jan 29, 2026

NeuShen Therapeutics, a Sino‑US biotech focused on central nervous system (CNS) disorders, announced the completion...

Company Deals

Organon Completes $465M JADA System Sale to Laborie Medical

Fineline Cube Jan 29, 2026

Organon (NYSE: OGN) announced the completed acquisition of its JADA system by Laborie Medical Technologies Corp....

Company Drug

MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study

Fineline Cube Jan 29, 2026

MicuRx Pharmaceuticals Inc., (SHA: 688373) a Sino‑US biopharmaceutical company, announced it has received approval from...

Company Drug

Huiyu Pharma HYP-6589 Gets NMPA Nod for NSCLC Osimertinib Combo

Fineline Cube Jan 29, 2026

Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553) announced that the National Medical Products Administration (NMPA)...

Company

Servier Oncology Revenue Drives 16% Growth, US Sales Surge 70%

Fineline Cube Jan 29, 2026

Servier announced a 16.2% year‑on‑year (YOY) revenue increase to EUR 6.9 billion (USD 7.52 billion) for the 2024/25 financial...

Company Drug

Changchun High‑Tech’s Firsekibart Filing Accepted for Non‑Infectious Uveitis

Fineline Cube Jan 29, 2026

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that the National Medical Products...

Company

Danaher Q4 Revenue Grows 3% to $24.6B on Biotech and Diagnostics Innovation

Fineline Cube Jan 29, 2026

Danaher Corporation (NYSE: DHR) reported fourth‑quarter and full‑year 2025 earnings with global revenues rising 3% year‑on‑year...

Company Deals Hospital

Distinct Healthcare IPO Hong Kong: Private Provider Seeks $36M HKEX Listing

Fineline Cube Jan 29, 2026

Distinct Healthcare Holdings Limited, a China‑based private healthcare service provider, released its prospectus this week...

Company

Merck Establishes Chongqing China Branch in Milestone Expansion

Fineline Cube Jan 29, 2026

Merck Sharp & Dohme (MSD, NYSE: MRK), a US‑based biopharmaceutical giant, announced the establishment of a...

Company Deals

Biogen’s Litifilimab Secures FDA Breakthrough Therapy Designation for Lupus

Fineline Cube Jan 29, 2026

Biogen Inc. (NASDAQ: BIIB) announced that its investigational litifilimab has received Breakthrough Therapy Designation (BTD) from...

Company Deals

Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal

Fineline Cube Jan 29, 2026

Seamless Therapeutics, a Germany‑based gene editing company, announced a global strategic research collaboration and license...

Company Drug

Sino Biopharm’s TQA3605 Meets Endpoint in Hepatitis B Phase II Trial

Fineline Cube Jan 28, 2026

Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Category 1 drug TQA3605 has met the primary...

Company Drug

J&J Darzalex Faspro Gets FDA Nod for NDMM D-VRd Regimen

Fineline Cube Jan 28, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) approved...

Posts pagination

1 … 80 81 82 … 696

Recent updates

  • Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression
  • Novartis’ Fabhalta Receives FDA Approval as First Oral Complement Factor B Inhibitor to Slow Renal Decline in Primary IgA Nephropathy
  • Shionogi’s Fetroja Receives FDA Acceptance for Pediatric sNDA Expanding Use to Gram-Negative Infections in Hospital-Acquired Pneumonia and Complicated UTIs
  • Merck’s Lipfendra Receives FDA Approval as First Oral PCSK9 Inhibitor for LDL Cholesterol Reduction in Hypercholesterolemia Patients
  • Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Company Drug

Novartis’ Fabhalta Receives FDA Approval as First Oral Complement Factor B Inhibitor to Slow Renal Decline in Primary IgA Nephropathy

Company Drug

Shionogi’s Fetroja Receives FDA Acceptance for Pediatric sNDA Expanding Use to Gram-Negative Infections in Hospital-Acquired Pneumonia and Complicated UTIs

Company Drug

Merck’s Lipfendra Receives FDA Approval as First Oral PCSK9 Inhibitor for LDL Cholesterol Reduction in Hypercholesterolemia Patients

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.